RCT: In patients with chronic kidney diseases and anemia not undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa in increasing hemoglobin levels and regarding cardiovascular outcomes.
7 Nov, 2021 | 20:17h | UTCDaprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this trial, daprodustat was as effective as darbepoetin alfa in increasing and maintaining hemoglobin levels in patients with CKD and anemia who were not receiving dialysis. #KidneyWk https://t.co/D2unQFLH6T pic.twitter.com/KqdLfVlkuD
— NEJM (@NEJM) November 5, 2021